Parexel International Corp. (NASDAQ:PRXL) – Investment analysts at First Analysis lowered their Q3 2017 earnings per share estimates for shares of Parexel International Corp. in a research report issued to clients and investors on Thursday. First Analysis analyst S. Schwartz now forecasts that the firm will post earnings per share of $1.05 for the quarter, down from their prior forecast of $1.09. First Analysis has a “Equal Weight” rating and a $62.00 price target on the stock. First Analysis also issued estimates for Parexel International Corp.’s FY2017 earnings at $3.75 EPS.

A number of other research firms also recently issued reports on PRXL. Credit Suisse Group AG reissued a “buy” rating on shares of Parexel International Corp. in a research report on Tuesday, September 27th. Deutsche Bank AG boosted their price target on Parexel International Corp. from $65.00 to $71.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Citigroup Inc. boosted their price target on Parexel International Corp. from $74.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Evercore ISI reissued a “buy” rating and set a $78.50 price target (up previously from $71.00) on shares of Parexel International Corp. in a research report on Friday, August 5th. Finally, Jefferies Group boosted their price target on Parexel International Corp. from $70.00 to $72.50 and gave the company a “hold” rating in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $67.00.

Earnings History and Estimates for Parexel International Corp. (NASDAQ:PRXL)

Shares of Parexel International Corp. (NASDAQ:PRXL) opened at 57.26 on Monday. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of 18.06 and a beta of 0.91. The stock’s 50 day moving average price is $63.11 and its 200 day moving average price is $64.19. Parexel International Corp. has a 12 month low of $51.16 and a 12 month high of $71.13.

Parexel International Corp. (NASDAQ:PRXL) last issued its earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.86 by $0.10. Parexel International Corp. had a return on equity of 30.71% and a net margin of 7.09%. The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $525.15 million. During the same period last year, the business posted $0.70 EPS. Parexel International Corp.’s revenue was down 2.2% on a year-over-year basis.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP increased its position in shares of Parexel International Corp. by 644.3% in the second quarter. Quantbot Technologies LP now owns 1,630 shares of the company’s stock worth $102,000 after buying an additional 1,411 shares in the last quarter. MSI Financial Services Inc boosted its stake in shares of Parexel International Corp. by 17.4% in the third quarter. MSI Financial Services Inc now owns 1,690 shares of the company’s stock valued at $117,000 after buying an additional 250 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Parexel International Corp. by 13.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,806 shares of the company’s stock valued at $125,000 after buying an additional 213 shares during the last quarter. Robecosam AG boosted its stake in shares of Parexel International Corp. by 40.1% in the second quarter. Robecosam AG now owns 2,200 shares of the company’s stock valued at $132,000 after buying an additional 630 shares during the last quarter. Finally, Acrospire Investment Management LLC boosted its stake in shares of Parexel International Corp. by 187.5% in the third quarter. Acrospire Investment Management LLC now owns 2,300 shares of the company’s stock valued at $160,000 after buying an additional 1,500 shares during the last quarter. 96.13% of the stock is owned by hedge funds and other institutional investors.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.